Inflammation plays a major role in colon carcinogenesis. Endogenously produced specialized proresolving lipid mediators (SPMs) play a central role in inflammation and tissue homeostasis, and have been implicated in carcinogenesis. We studied the associations of plasma levels of two SPMs [lipoxin A 4 (LXA 4 ) and resolvin D1(RvD1)] with risk for recurrent adenoma. In this pilot study, we used data and biosamples from an adenoma chemoprevention study investigating the effects of aspirin and/or folic acid on the occurrence of colorectal adenomas. In the parent study, 1121 participants with a recent adenoma were randomized to study agents to be taken until the next surveillance colonoscopy about 3 years later. In this pilot study, LXA 4 and RvD1 from samples taken near the end of study treatment were measured in a randomly selected subset of 200 participants. Commercially available ELISA kits to assay the analytes were validated using a metabololipidomic LC-MS/MS assay. Poisson regression with a robust error variance was used to calculate risk ratios and 95% confidence intervals. Plasma LXA 4 and RvD1 were not associated with the risk of adenoma occurrence. LXA 4 at the end of study follow-up was 32% (P = 0.01) proportionately higher in women compared to men. A similar non-significant trend toward higher levels among women was observed for RvD1. Our preliminary findings provided no evidence that plasma LXA 4 or RvD1 are associated with reduced risk of colorectal adenoma Abbreviations: 15-epi-LXA 4 , 15-epi-Lipoxin A 4 ; 15R-HETE, 15R-hydroxyeicosatetraenoic acid; AA, arachidonic acid; AFPPS, Aspirin/Folate Polyp Prevention
Inflammation plays a major role in colon carcinogenesis. Endogenously produced specialized proresolving lipid mediators (SPMs) play a central role in inflammation and tissue homeostasis, and have been implicated in carcinogenesis. We studied the associations of plasma levels of two SPMs [lipoxin A 4 (LXA 4 ) and resolvin D1(RvD1)] with risk for recurrent adenoma. In this pilot study, we used data and biosamples from an adenoma chemoprevention study investigating the effects of aspirin and/or folic acid on the occurrence of colorectal adenomas. In the parent study, 1121 participants with a recent adenoma were randomized to study agents to be taken until the next surveillance colonoscopy about 3 years later. In this pilot study, LXA 4 and RvD1 from samples taken near the end of study treatment were measured in a randomly selected subset of 200 participants. Commercially available ELISA kits to assay the analytes were validated using a metabololipidomic LC-MS/MS assay. Poisson regression with a robust error variance was used to calculate risk ratios and 95% confidence intervals. Plasma LXA 4 and RvD1 were not associated with the risk of adenoma occurrence. LXA 4 at the end of study follow-up was 32% (P = 0.01) proportionately higher in women compared to men. A similar non-significant trend toward higher levels among women was observed for RvD1. Our preliminary findings provided no evidence that plasma LXA 4 or RvD1 are associated with reduced risk of colorectal adenoma occurrence, but suggest LXA 4 may differ among men and women. Future studies focusing on SPM's local effects and levels in the colon are needed.
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| INTRODUCTION
It is well established that inflammation plays a major role in colon carcinogenesis.
1,2 Correspondingly, anti-inflammatory factors appear to suppress carcinogenesis in the large bowel. For example, aspirin, one of the most commonly used drugs in the world, is an antiinflammatory agent that is emerging as a potential chemopreventive agent against colorectal cancer (CRC). 2, 3 Lipoxins are endogenous eicosanoids, lipoxygenase pathway products of arachidonic acid, that have the potential to exert anti-neoplastic effects. 4 Lipoxins have recently been shown to mediate resolution of inflammation, 4, 5 and may also enhance epithelial integrity in various mucosal tissues. 6 Aspirin has a unique ability to initiate the formation of some lipoxins. Aspirin- [15-epi-LXA 4 and 15-epi-LXB 4 , the so-called "aspirin-triggered lipoxins" (ATLs)]. 7 In animal models and in vitro, both native and the aspirin-induced lipoxins promote apoptosis, affect tumorassociated macrophage activity profile, inhibit NFκB activity, cell proliferation, angiogenesis, and tumor progression. [8] [9] [10] [11] [12] [13] [14] [15] [16] Similar to lipoxins, resolvins, are anti-inflammatory and proresolving endogenous lipid mediators derived from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) by lipoxygenase, P450 and cyclooxygenase enzymes. 4 Though the anti-inflammatory and pro-resolving actions of resolvins are well documented, 17, 18 their potential roles in carcinogenesis have only recently begun to emerge. In addition to inhibition of inflammation/NFκB activity and promotion of repair of damaged tissue, these are likely to include modulation of transforming growth factor-β (TGF-β) signaling, [19] [20] [21] [22] an important pathway in colorectal carcinogenesis and tumor progression. 23 Therefore, to begin to understand the role of some specialized Details of subject eligibility, recruitment, randomization, treatment follow-up, and study outcomes have been previously described. 24, 25 Briefly, patients with a recent history of colorectal adenomas were For this pilot study, we randomly selected participants from each treatment group (69 assigned placebo, 63 assigned 81 mg, and 68 assigned 325 mg), and, within each treatment group, about the same number of participants from each outcome category (no recurrence, small tubular adenoma, and advanced adenoma). Participants were further restricted to those who were at least 50% compliant with study tablets at the time of blood draw, and had at least 1 mL of plasma stored in the biobank.
| Study outcomes
The primary outcome-adenoma occurrence-was determined by colonoscopy and confirmed by pathology review. All lesions removed from the large bowels of study subjects were reviewed by a single study pathologist. Polyps were classified as adenomatous, hyperplastic, serrated, or other findings; the degree of dysplasia was recorded. Low-risk adenomas were defined as solitary adenomatous polyps <1 cm in greatest diameter with tubular histology "small tubular adenoma." Advanced adenomas were defined as adenomatous polyps with an estimated diameter of ≥1 cm, or at least 25% villous component, any high-grade dysplasia, or invasive cancer.
| Laboratory measurements
The study was initially intended to investigate the aspirin-triggered Intra-plate coefficients of correlation (CVs) were 12.6% and 11.8% for LXA 4 and RvD1, respectively. Laboratory staff were blinded to the treatment group assignment and adenoma recurrence status of study participants, and treated all samples identically. Samples from each treatment and adenoma recurrence status group were randomly included in every batch. As this was a pilot study, LXA 4 and RvD1 were not measured at blood samples from study entry. However, the endof-treatment measurements reflect the subjects' environment during the period when the adenomas were forming.
| Statistical analyses
Levels of plasma biomarkers were natural log transformed to improve The baseline characteristics of the study participants selected for this analysis are shown in Table 1 . There were no statistically significant differences among the three arms with regard to demographic and lifestyle factors at the study entry. The three treatment arms were also similar with regard to the percentage of subjects who were randomly assigned to folic acid treatment. The baseline characteristics of the study participants were similar to those of the trial participants as a whole. 24 Among all study participants, peripheral blood plasma LXA 4 was strongly correlated with RvD1 (adjusted for batch, partial ρ = 0.77, P < 0.001). Similar correlations were found in each treatment group (data not shown). No significant correlations were found between either biomarker and body mass index (BMI) or age (all jρj < 0.07, all
Aspirin treatment was not associated with plasma LXA 4 or RvD1 obtained from peripheral blood. Interestingly, plasma levels of LXA 4 and RvD1 were proportionately 32% (P = 0.01) and 24% (P = 0.18) higher in women compared to men in all treatment groups combined (Table 2 ). Higher LXA 4 levels among women were observed within each treatment group (Supplementary Table S1 ). However, those for RvD1 were higher among women only in the placebo group (77%, P = 0.03, although the sex/RvD1 differences did not differ significantly over aspirin treatments (Supplementary Table S1 ).
There was no evidence that either plasma LXA 4 or RvD1 differed by adenoma outcome regardless of aspirin treatment group (Supplementary Table S2 ), nor were these measures associated with risk for any adenoma or with one or more advanced adenomas (Table 3) .
Although there were no significant associations of plasma LXA 4 LXA 4 in a gender-and age-specific manner. 30 Among women, the largest increase in 15-epi-LXA 4 after aspirin supplementation was observed in the oldest group (>55 years old); whereas among men, an opposite trend was noted: 15-epi-LXA 4 increased most in the youngest group. 30 We were not able to conduct a similar analysis in our trial as we did not measure the biomarkers at baseline.
Nonetheless, our data were supportive of gender-specific findings, as post-treatment concentrations of LXA 4 were higher in women compared with men. Furthermore, our study suggested that the association between LXA 4 and colorectal adenoma occurrence might differ by sex so that higher levels of LXA 4 are associated with lower risk among men, and with higher risk for colorectal adenomas occurrence among women; however, our study did not have sufficient power to determine whether these findings are due to chance.
This study is the first human study to investigate the association between plasma pro-resolving lipid mediators (LXA 4 and RvD1) and risk of colorectal adenomas. The strengths of the study include the high follow-up rate, the systemic collection of risk factor information at baseline and follow-up intervals as well as outcomes at the end of treatment; and the validation of lipid mediator measurements using the current state of the art assessment by LC-MS/MS profiling. 27 This study has several limitations. First, the fact that the 15-epi-LXA 4 ELISA kits we received did not measure the aspirin-triggered form of LXA 4 was not known at the beginning of our study but has now been demonstrated by our LC-MS/MS validation. Therefore, we were unable to assess the effect of daily aspirin intake on 15-epi-LXA 4 , as planned initially. Second, participants in this analysis had a previous history of at least one colorectal adenoma, potentially limiting the generalizability of the data. Third, we did not measure the local colon tissue at any time, or plasma eicosanoid concentrations at the study entry. However, the on-treatment measurements do reflect the subjects' metabolic milieu during the period when the adenomas were forming. Fourth, we had only a limited sample size to investigate risk of advanced adenoma occurrence, and conduct stratified analyzes, such as those by sex. Fifth, the biomarker measurements had relatively high CVs (<13%), were subject to batch effects (only RvD1), and could not be divided into more than two categories to study adenoma outcomes due to small sample size. Finally, additional local specialized pro-resolving lipid mediators such as protectin D1, maresins, or the E-series (resolvin E1), and other D-series resolvins (RvD2, RvD3, and RvD4) were not studied herein and remain of interest. [31] [32] [33] In conclusion, our preliminary findings do not support an association between plasma levels of the two pro-resolving lipid mediators LXA 4 and RvD1 and reduced risk of colorectal adenoma occurrence, though local actions in the colorectal mucosa remain to be evaluated. Finally, our results suggested that LXA 4 concentrations may differ among men and women.
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